These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
457 related articles for article (PubMed ID: 15373093)
1. [Risk of osteoporosis in postmenopausal women. When is bone density measurement indicated?]. MMW Fortschr Med; 2004 May; 146(21):63. PubMed ID: 15373093 [No Abstract] [Full Text] [Related]
5. Pharmacologic therapy for the treatment and prevention of osteoporosis. McClung B; McClung M Nurs Clin North Am; 2001 Sep; 36(3):433-40, viii. PubMed ID: 11532658 [TBL] [Abstract][Full Text] [Related]
7. Drugs for prevention and treatment of postmenopausal osteoporosis. Med Lett Drugs Ther; 2000 Oct; 42(1090):97-100. PubMed ID: 11035622 [No Abstract] [Full Text] [Related]
8. [SERM and quality of bone]. Sohen S Clin Calcium; 2004 Oct; 14(10):96-9. PubMed ID: 15577138 [TBL] [Abstract][Full Text] [Related]
9. [Osteoporosis compounds in general practice. That is REAL: in routine practice the better choice]. MMW Fortschr Med; 2007 Mar; 149(13):50. PubMed ID: 17672400 [No Abstract] [Full Text] [Related]
10. [Stability also depends on other parameters. Bone density--not a good indicator for fracture prevention]. MMW Fortschr Med; 2004 Aug; 146(31-32):53. PubMed ID: 15529718 [No Abstract] [Full Text] [Related]
11. Health-economic comparison of three recommended drugs for the treatment of osteoporosis. Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171 [TBL] [Abstract][Full Text] [Related]
12. Interleukin-18 (IL-18) and matrix metalloproteinase-9 (MMP-9) in post-menopausal osteoporosis. Maugeri D; Mamazza C; Lo Giudice F; Puglisi N; Muscoso EG; Rizzotto M; Testaì M; Bennati E; Lentini A; Panebianco P Arch Gerontol Geriatr; 2005; 40(3):299-305. PubMed ID: 15814163 [TBL] [Abstract][Full Text] [Related]
13. [Alendronate also for women without established osteoporosis?]. Klovning A; Norheim OF Tidsskr Nor Laegeforen; 2000 Apr; 120(11):1347-51. PubMed ID: 10868100 [No Abstract] [Full Text] [Related]
14. Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. Riggs BL; Melton LJ J Bone Miner Res; 2002 Jan; 17(1):11-4. PubMed ID: 11771656 [No Abstract] [Full Text] [Related]
15. Canadian consensus on osteoporosis. Preventing osteoporosis among postmenopausal women. Can Fam Physician; 2003 Apr; 49():487. PubMed ID: 12729244 [No Abstract] [Full Text] [Related]
16. Raloxifene. Not better than estrogen. Can Fam Physician; 2000 Aug; 46():1592-6, 1599-603. PubMed ID: 10955178 [TBL] [Abstract][Full Text] [Related]
17. A review of combination regimens for osteoporosis--prevention and treatment. Miller E; Kalin MF Int J Fertil Womens Med; 2002; 47(5):198-204. PubMed ID: 12469706 [TBL] [Abstract][Full Text] [Related]
18. [Evidence of raloxifene on postmenopausal osteoporosis]. Okano H Nihon Rinsho; 2007 Nov; 65 Suppl 9():374-80. PubMed ID: 18161135 [No Abstract] [Full Text] [Related]
19. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. Iwamoto J; Takeda T; Sato Y Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313 [TBL] [Abstract][Full Text] [Related]
20. [Effects of SERMs on bone health. Efficacy of SERM for incidence of fractures in osteoporotic patients with lifestyle-related diseases]. Sakai A; Nakamura T Clin Calcium; 2010 Mar; 20(3):322-9. PubMed ID: 20190361 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]